CJC-1295 with DAC Kit

Description

🧪 Product Profile: CJC-1295 without DAC

Product Name: CJC-1295 without DAC (Modified GRF 1-29)
CAS Number: 863288-34-0
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3367.89 g/mol
Amino Acid Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Purity: ≥98% (HPLC verified)
Formulation: Lyophilized white powder (standard vials: 5mg, 10mg, or custom specifications)

🔬 Key Characteristics

CJC-1295 without DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically engineered as a modified version of GRF (1-29) with enhanced stability. Unlike its counterpart CJC-1295 with DAC (Drug Affinity Complex), this variant lacks the plasma protein-binding moiety, resulting in a shorter half-life (~30 minutes) and pulsatile growth hormone (GH) secretion profile. Its structure includes D-amino acid substitutions (e.g., D-Ala) to resist enzymatic degradation, ensuring improved bioavailability in preclinical models.

⚙️ Mechanism of Action

• GHRH Receptor Agonism: Binds to GHRH receptors in the anterior pituitary gland, stimulating cyclic AMP (cAMP) signaling and calcium influx to trigger GH release in a dose-dependent manner.
• Pulsatile Secretion: Induces physiological GH pulses similar to endogenous secretion patterns, avoiding desensitization of pituitary somatotrophs compared to continuous GH exposure.
• IGF-1 Mediation: Promotes hepatic synthesis of insulin-like growth factor-1 (IGF-1), the primary mediator of GH’s anabolic effects on muscle, bone, and metabolism.

📊 Research Applications

• Endocrinology: Studies on GH axis regulation, pituitary function, and age-related GH decline models.
• Metabolic Research: Investigation of lean muscle preservation, fat oxidation, and insulin sensitivity in metabolic disorder models.
• Comparative Pharmacology: Contrast studies with CJC-1295 with DAC to evaluate half-life effects on GH/IGF-1 dynamics.
• Peptide Synergy: Combined use with GHRPs (e.g., Ipamorelin) to amplify GH secretion for enhanced anabolic or neuroprotective research outcomes.

💡 Product Features

• Stability: Lyophilized form stable for 24 months at 2-8°C under dry,避光 conditions; reconstitutes in sterile aqueous solvents (e.g., bacteriostatic water).
• Purity: ≥98% HPLC purity with low endotoxin levels (<10 EU/mg), suitable for in vitro and in vivo research.
• Pharmacokinetic Profile: Short-acting nature enables precise control over GH secretion timing in time-course experiments.

⚠️ Disclaimer

For Research Use Only: Not approved for human or veterinary clinical applications. Handling requires adherence to peptide research protocols, including proper reconstitution, storage, and biosafety measures.